Note 10 - Intangible Assets
|12 Months Ended|
Mar. 31, 2019
|Statement Line Items [Line Items]|
|Disclosure of intangible assets [text block]||
December 2012,the Corporation entered into a prepayment agreement with Neptune pursuant to which the Corporation exercised its option under the License Agreement to pay in advance all of the future royalties payable. The license allows the Corporation to exploit the intellectual property rights in order to develop novel active pharmaceutical ingredients (“APIs”) into commercial products for the prescription drugs market. The license Agreement, together with the Corporation own IP, allows the “freedom to operate” for CaPre, which is currently the Corporation’s only prescription drug candidate in development. The Corporation believes that upon the expiry of the last licensed Neptune patent in
2022,the Corporation’s expanding patent portfolio will cover CaPre, and that it will
notrequire any license from Neptune to support the commercialization of CaPre.
Amortization expense and impairment loss for the period ended
March 31, 2019and
one-month periods ended
March 31, 2017,and the
twelve-month period ended
2017have been recorded in “research and development expenses” in the statements of earnings and comprehensive loss.
The entire disclosure for intangible assets.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef